Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: Two placebo-controlled trials

American Journal of Psychiatry

Volumn 164, Issue 2, 2007, Pages 290-300

  Rynn, Moira A ^a   Riddle, Mark A ^b   Yeung, Paul P ^b   Kunz, Nadia R ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VENLAFAXINE;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADOLESCENT; ANOREXIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; INFECTION; MALE; NAUSEA; NERVOUSNESS; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; SUSTAINED DRUG RELEASE;

ADOLESCENT; AGE FACTORS; AMBULATORY CARE; ANXIETY DISORDERS; CHILD; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; HUMANS; META-ANALYSIS AS TOPIC; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33847253831     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2007.164.2.290     Document Type: Article

References (37)

1. Labellarte MJ, Ginsburg GS, Walkup JT, Riddle MA: The treatment of anxiety disorders in children and adolescents. Biol Psychiatry 1999; 46:1567-1578
2. Pine DS: Childhood anxiety disorders. Curr Opin Pediatr 1997; 9:329-338
3. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME: NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 2000; 39:28-38
4. Costello EJ, Angold A: Epidemiology, in Anxiety Disorders in Children and Adolescents. Edited by March JS. New York, Guilford, 1995, pp 109-115
5. Costello EJ, Janiszewski S: Who gets treated? factors associated with referral in children with psychiatric disorders. Acta Psychiatr Scand 1990; 81:523-529
6. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB: Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 1999; 38:557-565
7. Jensen PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, Hoven C, Bird HR, Bauermeister JJ, Payne JD: Are stimulants overprescribed? treatment of ADHD in four US communities. J Am Acad Child Adolesc Psychiatry 1999; 38:797-804
8. Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MA: Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003; 157:17-25
9. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160:749-756
10. Allgulander C, Dahl AA, Austin C, Morris PLP, Sogaard JA, Fayyad R, Kutcher SP, Clary CM: Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004; 161:1642-1649
11. Davidson JR, Bose A, Korotzer A, Zheng H: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19:234-240
12. Bernstein GA, Layne AE: Separation anxiety disorder and generalized anxiety disorder, in Child and Adolescent. Edited by Wiener JM, Dulcan MK. Washington DC, American Psychiatric Publishing, 2004, pp 557-573
13. Fairbanks JM, Pine DS, Tancer NK, Dummit ES III, Kentgen LM, Martin J, Asche BK, Klein RG: Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol 1997; 7:17-29
14. Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, Brodsky M: Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994; 33:993-999
15. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001; 344:1279-1285
16. Rynn MA, Siqueland L, Rickels K: Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158:2008-2014
17. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA: Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42:415-423
18. Rickels K, Pollack MH, Sheehan DV, Haskins JT: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157:968-974
19. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 2000; 283:3082-3088
20. Chaput F, Fisher P, Klein R, Greenhill L, Shaffer D: The Columbia KSADS (Schedule for Affective Disorders and Schizophrenia for School Aged Children). New York, New York State Psychiatric Institute, Divison of Child and Adolescent Psychiatry, 1999
21. Puig-Antich J, Chambers WJ: Schedule for Affective Disorders and Schizophrenia for School-Age Children (KIDDIE-SADS). New York, New York State Psychiatric Institute, Biometrics Research, 1978
22. Poznanski EO, Freeman LN, Mokros HB: Children's Depression Rating Scale - Revised. Psychopharmacol Bull 1985; 21:979-989
23. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
24. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36:980-988
25. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry 2002; 41:1061-1069
26. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
27. Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J, Neer SM: The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 1997; 36:545-553
28. Birmaher B, Brent DA, Chiappetta L, Bridge J, Monga S, Baugher M: Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry 1999; 38:1230-1236
29. Mallinckrodt CH, Raskin J, Wohlreich MM, Watkin JG, Detke MJ: The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry 2004; 4:26
30. Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken LS, Muenz LR, Thase ME, Weiss RD, Gastfriend DR, Woody GE, Barber JP, Butler SF, Daley D, Salloum I, Bishop S, Najavits LM, Lis J, Mercer D, Griffin ML, Moras K, Beck AT: Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999; 56:493-502
31. Allgulander C, Hackett D, Salinas E: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179:15-22
32. Ialongo N, Edelsohn G, Werthamer-Larsson L, Crockett L, Kellam S: The significance of self-reported anxious symptoms in first grade children: prediction to anxious symptoms and adaptive functioning in fifth grade. J Child Psychol Psychiatry 1995; 36:427-437
33. Davidson JR: Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62(suppl 11):46-50
34. Masi G, Millepiedi S, Mucci M, Poli P, Bertini N, Milantoni L: Generalized anxiety disorder in referred children and adolescents. J Am Acad Child Adolesc Psychiatry 2004; 43:752-760
35. Grunbaum JA, Kann L, Kinchen S, Ross J, Hawkins J, Lowry R, Harris WA, McManus T, Chyen D, Collins J: Youth risk behavior surveillance - United States, 2003. MMWR Surveill Summ 2004; 53:1-96
36. Kusiak V: Dear health care professional (letter on venlafaxine). Collegeville, Penn, Wyeth Pharmaceuticals, Aug 22, 2003
37. Hammad TA: Review and Evaluation of Clinical Data. Washington, DC, Food and Drug Administration, Center for Drug Evaluation and Research, Aug 16, 2004. Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10- TAB08-Hammads-Review.pdf